Search

Displaying results 4351 - 4360 of 10000 in total
  1. Drug

    Actelion-1

    go.drugbank.com/drugs/DB05367
    Experimental

    Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.

  2. Drug

    TGAAC09

    go.drugbank.com/drugs/DB06363
    Investigational

    It was under investigation in clinical trials NCT00482027 and NCT00888446 for the treatment of HIV Infection. … tgAAC09 is an investigational vaccine that utilizes an AAV vector to deliver genes that encode HIV proteins.

  3. Drug

    Nimesulide

    go.drugbank.com/drugs/DB04743
    ApprovedInvestigationalWithdrawn

    Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries. … Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.

    Products: NI-M-DOL® (NIMESULIDA SUSPENSION), MESULID SUSPENSION PARA ADMINISTRACIÓN EN GOTAS
  4. Drug

    Matuzumab

    go.drugbank.com/drugs/DB05101
    Investigational

    Matuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment. … It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.

  5. Drug

    Cethromycin

    go.drugbank.com/drugs/DB06419
    Investigational

    Cethromycin is a 3-keto (ketolide) derivative of erythromycin A with an 11,12-carbamate group and an O-6-linked aromatic ring system. … [L14006, A203369] However, after completing phase III clinical trials, it was deemed safe but not sufficiently efficacious by the FDA.

  6. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. … The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this

  7. Drug

    TAFA-93

    go.drugbank.com/drugs/DB05887
    Experimental

    TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation

  8. Drug

    Regramostim

    go.drugbank.com/drugs/DB05386
    Investigational

    Endothelial cells and fibroblasts can also produce GM-CSF after exposure to TNF-α, IL-1, IL-2 and IFN-γ. GM-CSF is found associated with extracellular matrix and in membrane-bound formats too. … Regramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and macrophages.

  9. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    mutations in the kinase domain of FGFR. … It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively.

  10. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. … It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.